Web NewDrugInformation.com

M.V.C. 9+3 Drug - M.V.C. 9+3 The trade name of the product as shown on the labeling. Dosage - INJECTABLE; INJECTION The product dosage form and route separated by a semi-colon. Active Ingredient(s) - Ascorbic Acid; Biotin; Cyanocobalamin; Dexpanthenol; Ergocalciferol; Folic Acid; Niacinamide; Pyridoxine Hydrochloride; Riboflavin Phosphate Sodium; Thiamine Hydrochloride; Vitamin A; Vitamin E Multiple ingredients are in alphabetical order. Strength - 10MG/ML;0.006MG/ML;0.5UGM/ML;1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML;0.4MG/ML;0.36MG/ML;0.3MG/ML;330 UNITS/ML;1 IU/ML The potency of the active ingredient(s), Ascorbic Acid; Biotin; Cyanocobalamin; Dexpanthenol; Ergocalciferol; Folic Acid; Niacinamide; Pyridoxine Hydrochloride; Riboflavin Phosphate Sodium; Thiamine Hydrochloride; Vitamin A; Vitamin E. May repeat for multiple part products. Applicant - AM PHARM PARTNERS The firm name holding legal responsibility for M.V.C. 9+3. The firm name is condensed to a maximum twenty character unique string. New Drug Application (NDA) Number - 018440 The FDA assigned number to M.V.C. 9+3. Format is nnnnnn. Product Number - 002 The FDA assigned number to identify M.V.C. 9+3. Each strength is a separate product. May repeat for multiple part products. Format is nnn. Therapeutic Equivalence (TE) Code - The TE Code indicates the therapeutic equivalence rating of generic to innovator Rx products. Approval Date - Aug 8, 1985 The date M.V.C. 9+3 was approved as stated in the FDA approval letter to the applicant. The format is Mmm dd, yyyy. Products approved prior to the January 1, 1982 contain the phrase: "Approved prior to Jan 1, 1982". Reference Listed Drug (RLD) - No The pioneer or innovator of M.V.C. 9+3. The RLD identifies the product Abbreviated New Drug Applications (ANDA) use as a reference. Format is Yes or No. Type - DISCN The group or category of approved drugs M.V.C. 9+3 is in. Format is RX, OTC, DISCN. Applicant Full Name - American Pharmaceutical Partners Inc The full name of the firm holding legal responsibility for the new application of M.V.C. 9+3. M.V.C. 9+3 Abilify 5mg Tablet; Oral Trisenox 1mg/ml Injectable; Injection Septocaine 4%;eq 0.01mg Base/ml Injectable; Injection Infuvite Pediatric 80mg/vial;0.02mg/vial;400 Iu/vial;0.001mg/vial;5mg/vial;0.14mg/vial;17mg/vial;1mg/vial;1.4mg/vial;1.2mg/vial;7 Iu/vial;2,300 Iu/vial;0.2mg/vial Injectable; Iv (infusion) Infuvite Pediatric (pharmacy Bulk Package) 80mg/vial;0.02mg/vial;400 Iu/vial;0.001mg/vial;5mg/vial;0.14mg/vial;17mg/vial;1mg/vial;1.4mg/vial;1.2mg/vial;7 Iu/vial;2,300 Iu/vial;0.2mg/vial Injectable; Iv (infusion) M.V.I. Pediatric 80mg/vial;0.02mg/vial;0.001mg/vial;5mg/vial;0.01mg/vial;0.14mg/vial;17mg/vial;0.2mg/vial;1mg/vial;1.4mg/vial;eq 1.2mg Base/vial;0.7mg/vial;7mg/vial For Solution; Iv (infusion) Berocca Pn 50mg/ml;0.03mg/ml;0.0025mg/ml;7.5mg/ml;100 Iu/ml;0.2mg/ml;20mg/ml;2mg/ml;1.8mg/ml;1.5mg/ml;1,650 Iu/ml;5 Iu/ml Injectable; Injection M.V.C. 9+3 10mg/ml;0.006mg/ml;0.5ugm/ml;1.5mg/ml;20 Iu/ml;0.04mg/ml;4mg/ml;0.4mg/ml;0.36mg/ml;0.3mg/ml;330 Units/ml;1 Iu/ml Injectable; Injection Abilify 2mg Tablet; Oral Abilify 30mg Tablet; Oral NewDrugInformation